Adverse events of thiopurine immunomodulators in patients with inflammatory bowel disease.

[1]  H. Sokol,et al.  Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine , 2009, Alimentary pharmacology & therapeutics.

[2]  C. Girelli,et al.  The use of thiopurines for the treatment of inflammatory bowel diseases in clinical practice. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[3]  J. Gisbert,et al.  Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine‐induced pancreatitis , 2008, Alimentary pharmacology & therapeutics.

[4]  J. Gisbert,et al.  Thiopurine-Induced Myelotoxicity in Patients With Inflammatory Bowel Disease: A Review , 2008, The American Journal of Gastroenterology.

[5]  M. De Vos,et al.  Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine , 2007, Gut.

[6]  J. Mate,et al.  Liver injury in inflammatory bowel disease: Long‐term follow‐up study of 786 patients , 2007, Inflammatory bowel diseases.

[7]  J. Mate,et al.  Thiopurine-Induced Liver Injury in Patients With Inflammatory Bowel Disease: A Systematic Review , 2007, The American Journal of Gastroenterology.

[8]  J. Mate,et al.  Thiopurine Methyltransferase Activity in Spain: A Study of 14,545 Patients , 2007, Digestive Diseases and Sciences.

[9]  S. Schoenberg,et al.  Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy. , 2006, European journal of gastroenterology & hepatology.

[10]  W. Tremaine,et al.  American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. , 2006, Gastroenterology.

[11]  F. Dasí,et al.  Incidence, risk factors and clinical course of thiopurine‐induced liver injury in patients with inflammatory bowel disease , 2005, Alimentary pharmacology & therapeutics.

[12]  J. Satsangi,et al.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[13]  Wolfgang Schima,et al.  A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. , 2005, Journal of hepatology.

[14]  M. Gassull,et al.  6-Mercaptopurine in patients with inflammatory bowel disease and previous digestive intolerance of azathioprine , 2005, Scandinavian journal of gastroenterology.

[15]  J. J. Homan van der Heide,et al.  Increased incidence of azathioprine‐induced pancreatitis in Crohn's disease compared with other diseases , 2004, Alimentary pharmacology & therapeutics.

[16]  W. Selby,et al.  Use of 6-Mercaptopurine in Patients with Inflammatory Bowel Disease Previously Intolerant of Azathioprine , 2000, Digestive Diseases and Sciences.

[17]  B. Korelitz,et al.  Cumulative Experience With Short- and Long-Term Toxicity to 6-Mercaptopurine in the Treatment of Crohn's Disease and Ulcerative Colitis , 2003, Journal of clinical gastroenterology.

[18]  S. Targan,et al.  6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. , 2003, Gastroenterology.

[19]  J. Gisbert,et al.  Terapia individualizada con azatioprina o 6-mercaptopurina mediante monitorización de la actividad de la tiopurina metiltransferasa (TPMT) , 2002 .

[20]  J. Mate,et al.  [Individualized therapy with azathioprine or 6-mercaptopurine by monitoring thiopurine methyl-transferase (TPMT) activity]. , 2002, Revista clinica espanola.

[21]  V. Garrigues,et al.  Adverse effects of azathioprine in the treatment of inflammatory bowel disease. , 2001, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[22]  S. Krähenbühl,et al.  Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis. , 2001, European journal of gastroenterology & hepatology.

[23]  G. Mazzacca,et al.  Hepatitis related to cytomegalovirus infection in two patients with Crohn's disease treated with azathioprine. , 2000, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[24]  G. Lichtenstein,et al.  Azathioprine or 6-mercaptopurine for inflammatory bowel disease: do risks outweigh benefits? , 2000, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[25]  I. Arnott,et al.  Portal hypertension in the presence of minimal liver damage in Crohn's disease on long-term azathioprine: possible endothelial cell injury. , 2000, European journal of gastroenterology & hepatology.

[26]  B. Korelitz,et al.  Allergic reactions to 6-mercaptopurine during treatment of inflammatory bowel disease. , 1999, Journal of clinical gastroenterology.

[27]  B. Kirschner,et al.  Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. , 1998, Gastroenterology.

[28]  G. Fick,et al.  Azathioprine and 6-Mercaptopurine in Crohn Disease , 1995, Annals of Internal Medicine.

[29]  M. Kamm,et al.  Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. , 1993, Gut.

[30]  M. Chevallier,et al.  Azathioprine induced liver disease: nodular regenerative hyperplasia of the liver and perivenous fibrosis in a patient treated for multiple sclerosis. , 1991, Gut.

[31]  S. Meltzer,et al.  6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. , 1989, Annals of internal medicine.